Treatment of Advanced and Metastatic Solid Tumors With MIL97
- Conditions
- Advanced or Metastatic Solid Tumor
- Interventions
- Drug: Recombinant Humanized Monoclonal Antibody MIL97 for Injection
- Registration Number
- NCT04965077
- Lead Sponsor
- Beijing Mabworks Biotech Co., Ltd.
- Brief Summary
This is a Phase 1, global, multi-center, open-label, multiple-dose, first-in-human study of MIL97 to evaluate the safety, tolerability, pharmacokinetics, biomarkers and efficacy in subjects with advanced or metastatic solid tumor. The study consists of a dose escalation phase and a dose expansion phase. An accelerated titration design (cohorts 1-2 only) followed by 3+3 dose-escalation design will be used in dose escalation phase.
The starting dose for dose escalation phase is 0.01 mg/kg Q3W, followed by 5 dose cohorts (0.03mg/kg Q3W, 0.1mg/kg Q3W, 0.2mg/kg Q3W, 0.3mg/kg Q3W and 0.45mg/kg Q3W). Duration of dose limiting toxicity (DLT) observation is 21 days. Based on data of 3-week treatment regimen, one or two dose levels may be chosen for Q2w regimen. Duration of dose limiting toxicity (DLT) observation is 28 days.
One or two dose cohorts will be chosen (either 2-week regimen or 3-week regimen cohorts) to expand to total of 10 subjects in each cohort for further exploration of PK as well as safety and efficacy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 62
- Adult patients, >=18 years of age;
- Diagnosis of Refractory/relapsed metastatic and/or unresectable solid tumors;
- At least one extracranial measurable unirradiated lesion or evaluable lesion (recist v1.1) ;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1Life expectancy >=3 months;
- Sufficient organ and bone marrow function within 7 days before enrollment;
- Life expectancy >=12 weeks;
- Able and willing to provide written informed consent and to comply with the study protocol.
- have a history of myocardial infarction within 6 months or a history of arterial thromboembolic event within 3 months before the first dose;
- Comorbidity that would interfere with therapy, including interstitial pneumonia, symptomatic congestive heart failure; unstable angina, uncontrolled hypertension; ongoing cardiac arrhythmia ≥ CTCAE 5.0 Grade 3, active coagulopathy, uncontrolled diabetes, QTcF>450ms (Male) or QTcF>470ms (Female) at screening;
- Patients have a known or suspected history of an autoimmune disorder, except for the following: Type 1 diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders such as vitiligo, or alopecia not requiring systemic therapy, or conditions not expected to recur in the absence of an external trigger are eligible;
- Have a history of manifested central nervous system (CNS) metastases or have primary brain tumor. Patients with known or suspected leptomeningeal disease or cord compression;
- Receipt of allograft or allogeneic hematopoietic stem cell transplantation;
- Patients have another active invasive malignancy, but history of a non-invasive malignancy and history of malignancy that is in complete remission after treatment with curative intent are allowed;
- Active known clinically serious infections are required intravenous antibiotic treatment;
- Have a history of primary immunodeficiency, including but not limited with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness;
- Active and clinical significant bacterial, fungal, or viral infection including hepatitis B virus (HBV) or hepatitis C (HCV) (Hepatitis B should be confirmed as HBV surface antigen (HBsAg) positive or HBV core antibody (HBcAb) positive with HBV DNA above ULN);
- Any antitumor therapy within prior 4 weeks (including chemotherapy, targeted therapy, hormone therapy, immunotherapy, radiotherapy, tumor embolization, etc), except for palliative radiotherapy for relief bone pain;
- Major surgery within prior 4 weeks or expected to require major surgery during study treatment (Major surgery: laparotomy, thoracotomy, and internal organs excision by laparoscopic surgery);
- Patients have concurrent received or used an immunosuppressive agent within 14 days before study treatment, with the following exceptions and notes: Systemic steroids at physiologic doses, intranasal, inhaled, topical, intra-articular, and ocular corticosteroids with minimal systemic absorption, transient courses of steroids may be approved by the Medical Monitor;
- Previous exposure to CD40 antibodies;
- Patients received a live attenuated vaccine within 28 days before study treatment and plan to receive live vaccines during the study unless approved by both investigator and sponsor;
- Toxicities due to prior therapy are unresolved to ≤ CTCAE 5.0 Grade 1 except for AEs not constituting a safety risk to the patient based on the judgment of investigators;
- History of clinically significant sensitivity or allergy to MIL97, their excipients, or intravenous gamma globulin;
- Females who are pregnant or lactating or who intend to become pregnant during the clinical trial period and within 6 months after discontinuation of study treatment. Female or Male who refused using birth control during the clinical trial period and within 6 months after discontinuation of study treatment;
- Participation in a therapeutic clinical study within 4 weeks for biological treatments, and within 1 week or 5 half-lives for small-molecule agents, before study drug treatment, or current participation in other therapeutic investigational procedures;
- Patients who have any clinically significant psychiatric, social, or medical condition that, in the opinion of the investigator, could increase the patient's risk, interfere with protocol adherence, or affect the patient's ability to give informed consent are ineligible to participate in the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description MIL97 Recombinant Humanized Monoclonal Antibody MIL97 for Injection -
- Primary Outcome Measures
Name Time Method The incidence of MIL97 treatment-emergent adverse events in patients with advanced or metastatic solid tumor up to 2.5 year after enrollment incidence of AEs and SAEs assessed by NCI CTCAE v5.0.
- Secondary Outcome Measures
Name Time Method Pharmacokinetics: AUC up to 1.5 year after enrollment The area under the curve (AUC) of serum concentration of the drug after the administration
Pharmacokinetics: Cmax; up to 1.5 year after enrollment Maximum concentration (Cmax) of the drug after administration
Objective response rate (ORR); up to 2.5 year after enrollment To evaluate preliminary anti-tumor activity of MIL97 in subjects with advanced or metastatic solid tumor. ORR includes complete remission (CR) and partial remission (PR) assessed by RECIST v1.1 criteria.
Duration of response (DoR); up to 2.5 year after enrollment DOR is defined as the time from the initial response (CR or PR) to the time of disease progression or death, whichever occurs first.
Progression free survival (PFS); up to 2.5 year after enrollment Defined as the time from the first day of study treatment to disease progression or death, whichever occurs first.
The overall survival for patients with advanced or metastatic solid tumor; up to 2.5 year after enrollment Defined as the time from the first day of study treatment to disease progression or death, whichever occurs first.
The Disease control rate for patients with advanced or metastatic solid tumor; up to 2.5 year after enrollment Defined defined as the proportion of patients with objective evidence of CR, PR, or SD.
Immunogenicity; up to 2.5 year after enrollment Anti-Drug Antibodies (ADA) will be tested and percentage of ADA positive patients will be calculated to evaluate immunogenicity of MIL97.
Biomarkers; up to 2.5 year after enrollment measurement of CD80, CD86 and cytokines in human plasma
Trial Locations
- Locations (1)
Chinese PLA General Hospital
🇨🇳Beijing, Beijing, China